Eli Lilly | LLY - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 14.39B 1.85B 2026-06
Abbott USD 6.65B 787M 2026-06
ALKERMES USD 375.31M 43.98M 2026-06
Amgen USD 5.87B 1.02B 2026-03
AstraZeneca USD 12.86B 251M 2026-06
Baxter International USD 1.14B 251M 2026-06
Biogen USD 2.12B 307M 2026-06
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Coherus Biosciences USD 8.7M 853K 2025-12
Drreddys Laboratories INR 43.04B 3.77B 2026-03
Eli Lilly USD 16.22B 301.7M 2026-03
Gilead Sciences USD 6.8B 1.29B 2026-06
GlaxoSmithKline GBP 6.51B 757M 2026-06
Glaxosmithkline GBP 5.75B 2.99B 2026-03
J&J USD 18.55B 1.31B 2026-06
Medtronic USD 6.36B 355M 2026-06
Merck USD 12.09B 1.24B 2026-03
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novartis USD 11.24B 1.18B 2026-06
Novartis USD 10.07B 758M 2026-03
Novo Nordisk DKK 64.01B 1.19B 2025-06
Perrigo USD 313.9M 11.6M 2026-06
Pfizer USD -248M 11.29B 2026-06
Phibro Animal Health USD 133.5M 12.6M 2025-12
Prestige Brands USD 136.19M 10.11M 2026-06
Regeneron Pharmaceuticals USD 3.71B 778.2M 2026-06
Roche Holding CHF 22.69B 600M 2026-06
Sanofi EUR 8.71B 602M 2026-06
Sanofi EUR 8.11B 343M 2026-03
United Therapeutics USD 683.8M 35.7M 2026-06
Zoetis USD 1.76B 140M 2026-06